CHROMADEX CORPORATION (NASDAQ:CDXC) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
entered into an indemnity agreement (the Indemnity Agreement)
with each of its existing directors and executive officers. The
Indemnity Agreements supersede any indemnity agreement that the
Company previously entered into with its directors or executive
officers.
of the Company previously approved on November 8, 2016, provides
that the Company may be required to indemnify each of the covered
directors and executive officers for claims arising in such
person’s capacity as a director, executive officer, employee or
other agent of the Company. The rights of each director or
executive officer party to an Indemnity Agreement are in addition
to any other rights such person may have under the Company’s
Amended and Restated Certificate of Incorporation, Amended and
Restated Bylaws or otherwise under Delaware law.
to be complete and is qualified in its entirety by reference to
the form of Indemnity Agreement, a copy of which is attached to
this Current Report on Form 8-K as Exhibit 10.1.
|
Exhibit No.
|
Description
|
|
|
10.1
|
Form of Indemnity Agreement
|
About CHROMADEX CORPORATION (NASDAQ:CDXC)
Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks. CHROMADEX CORPORATION (NASDAQ:CDXC) Recent Trading Information
CHROMADEX CORPORATION (NASDAQ:CDXC) closed its last trading session up +0.02 at 2.50 with 100,405 shares trading hands.
